Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer

DISEASE CHARACTERISTICS:

* Meets 1 of the following criteria:

  * Newly diagnosed (within 30 calendar days of diagnosis) stage I or II breast cancer

    * Node-negative or node-positive disease
  * Newly diagnosed ductal carcinoma in situ (stage 0) of the breast
  * At high risk of developing breast cancer, as indicated by at least 1 of the following criteria:

    * Gail model 5-year risk score ≥ 1.66%
    * Gail model lifetime-risk estimate ≥ 20%
    * Known deleterious BRCA 1 or 2 gene mutation carrier
    * History of lobular carcinoma in situ or atypical ductal or lobular hyperplasia
  * At low or average risk of developing breast cancer (control group)

    * Gail model 5-year risk score \< 1.66% or lifetime risk \< 20%
* No advanced breast cancer
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* Pre- or post-menopausal

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy for breast cancer or any other cancer
* More than 3 months since prior and no concurrent estrogen or other hormones
* More than 3 months since prior oral contraceptives
* No concurrent selective estrogen receptor modulators (tamoxifen citrate or raloxifene)
* No concurrent aromatase inhibitors